Nootropics & Brain Supplements

A Supplement Eased “Chemo Brain” in a Small UCLA Trial, but There Was No Placebo Group

A plain white supplement bottle with a few white capsules beside a glass of water and a steaming beige mug on a light oak table, with green plants and soft morning light behind

“A simple supplement may help clear brain fog after cancer” is the kind of headline that spreads quickly, and this week it did. The trial behind it, from UCLA, tested oxaloacetate in breast cancer survivors who were still struggling with memory and concentration years after diagnosis. The results look striking on paper. They also come from 16 women and a study with no placebo group, and that design affects how much any of it can tell you.

What the Researchers Did

A team at the UCLA Health Jonsson Comprehensive Cancer Center, led by Dr. Patricia Ganz, recruited 18 women who had been diagnosed with early-stage breast cancer one to five years earlier and who reported significant thinking problems. Their average age was about 50. Most had been through chemotherapy, and nearly 90% were still taking endocrine (hormone-blocking) therapy during the study.

Every participant took 500 mg of oxaloacetate twice a day for eight weeks. Researchers measured self-reported cognitive symptoms, ran standard tests of attention, memory, processing speed and executive function, and tracked fatigue, sleep, mood and side effects. Sixteen women finished. The results appeared in JCO Oncology Advances in October 2026, and ScienceDaily carried the story on November 9.

What They Found

The headline number comes from the trial’s primary measure, the perceived cognitive impairment scale of the FACT-Cog questionnaire, where higher scores mean fewer problems. The group’s average rose from 29.1 to 55.5, which the researchers describe as moving from the impaired range into the normal range. The trial registration defined a positive response as a gain of just 4 points, and all 16 women who completed the study reported meaningful improvement. Gains were already visible at four weeks and generally kept growing through week eight.

Participants also reported less fatigue, including mental fatigue, and better physical functioning. On the objective tests, processing speed and executive function improved, though the authors call those findings preliminary.

The side effects were mainly digestive: indigestion, bloating, constipation, diarrhea and nausea. Two of the 18 women stopped for that reason. No serious adverse events were reported.

Why “No Placebo Group” Matters So Much Here

A single-arm trial gives everyone the treatment and compares them only with themselves. That is a sensible way to check safety and decide whether a bigger study is worth running, which is exactly what this was designed to do. It can’t show that the supplement caused the improvement, and this particular setup is especially prone to overstating benefits, for three reasons.

The main outcome is a self-report. People who know they are taking something that might help tend to rate their symptoms as better, and questionnaire measures like FACT-Cog are more sensitive to that expectation effect than lab tests are.

People enrolled at their worst. The women were chosen because their symptoms were significant. Scores taken at a low point often drift back toward average on their own, a pattern statisticians call regression to the mean.

Cancer-related brain fog can ease with time. For many survivors, symptoms improve gradually in the years after treatment. Without a comparison group, some of the change seen over eight weeks may simply be that recovery continuing.

The repeated tests also cut both ways: people often score better the second time they take the same kind of cognitive test, simply from practice. None of this means oxaloacetate did nothing. It means this study can’t separate its effect from these other explanations. The authors say the same, and they are now preparing a randomized, placebo-controlled phase II trial expected to open in late 2026.

Working Around Foggy Days

When concentration is unreliable, shorter, clearly defined work blocks with real breaks are often easier to sustain than long sessions. Our free Focus Timer lets you set the length that suits you.

Open the Focus Timer →

Why Oxaloacetate, of All Things?

Oxaloacetate is a natural compound in the cell’s energy cycle, and it also helps regulate glutamate, one of the brain’s main signaling chemicals. The UCLA team’s idea is that inflammation from cancer and its treatment may disturb both brain energy production and glutamate signaling, so a compound involved in both could help.

That’s a reasonable hypothesis, not an established mechanism. Earlier human evidence is thin. In a University of Kansas trial published in 2021, 30 people with Alzheimer’s disease took one of two oxaloacetate doses for a month. The higher dose was safe and changed brain energy markers on imaging, but cognitive scores didn’t improve. That was a different population and question, but it shows that a compound can reach its biological target without that turning into better thinking. We saw the same pattern recently when a two-year fish oil trial raised brain DHA without helping memory.

One more detail worth knowing: the trial was funded partly by the Breast Cancer Research Foundation and the National Cancer Institute, and its ClinicalTrials.gov record (NCT04290897) also lists a supplement company, MetVital, Inc., as a collaborator. Industry involvement is common in supplement research and doesn’t invalidate a study, but it’s one more reason to wait for the controlled trial.

What This Means If You’re Dealing With Brain Fog

If you’re a cancer survivor, this is a reason for cautious hope and a good topic to raise with your oncology team, not a reason to start buying oxaloacetate. Oxaloacetate is sold as a supplement, but the dose, formulation and safety profile in this trial came with medical oversight. Anyone on endocrine therapy or other ongoing treatment should check before adding anything new.

For everyone else interested in focus supplements, the broader lesson is about how to read headlines. Ask three questions before trusting a “supplement clears brain fog” claim: Was there a placebo group? How many people took part? Was the main result a self-report or an objective test? This study answers no, 16 and self-report. That’s fine for a pilot study, but it isn’t enough to change what you buy. Our guide to science-backed nootropics applies the same filter across more popular options.

Cancer-related cognitive impairment is real, common and under-treated, so any lead is worth following. This is a lead, not an answer, and the coming controlled trial will show whether it holds up.

Frequently Asked Questions

Does oxaloacetate cure chemo brain?

There isn’t enough evidence to say that. In a small UCLA trial without a placebo group, all 16 breast cancer survivors who completed eight weeks of oxaloacetate reported better cognitive symptoms, but the design can’t show the supplement caused the improvement. A placebo-controlled trial is planned.

What dose of oxaloacetate was used in the study?

Participants took 500 mg twice a day, for 1,000 mg daily, over eight weeks. The study used a specific form called anhydrous enol-oxaloacetate under medical supervision. Talk to your care team before trying it yourself.

What were the side effects?

Mostly digestive problems: indigestion, bloating, constipation, diarrhea and nausea. Two of the 18 women stopped taking it because of them. No serious adverse events were reported.

Source: ScienceDaily — "A Simple Supplement May Help Clear Brain Fog After Cancer," November 9, 2026. https://www.sciencedaily.com/releases/2026/11/261104084013.htm — reporting on Ganz PA, Van Dyk K, Crespi CM, Petersen L, Sedrak MS, Bower JE. "Results From a Phase II Single-Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors," JCO Oncology Advances, 2026;3(4) (DOI 10.1200/OA-26-00063). Additional details from the UCLA Health news release, October 20, 2026, https://www.uclahealth.org/news/release/nutritional-supplement-may-help-ease-brain-fog-after-breast, and the trial registration, https://clinicaltrials.gov/study/NCT04290897. Background on the earlier Alzheimer’s trial: Vidoni ED et al., "Safety and target engagement profile of two oxaloacetate doses in Alzheimer’s patients," Alzheimer’s & Dementia, 2021;17(1):7–17.

Health disclaimer: This article summarizes published research and is for educational purposes only. It is not medical advice. If you have had cancer treatment or are taking endocrine therapy or any other medication, talk with your oncology team or another qualified healthcare professional before starting any supplement, and raise new or worsening memory problems with them.

FocusWaveHub Editorial Team

FocusWaveHub Editorial Team

Editorial & Research Team

The FocusWaveHub editorial team synthesizes peer-reviewed research on cognitive performance, attention science, and evidence-based productivity. About our editorial approach →